Literature DB >> 24521454

Targeting the Fc receptor in autoimmune disease.

Xinrui Li1, Robert P Kimberly.   

Abstract

INTRODUCTION: The Fc receptors (FcRs) and their interactions with immunoglobulin and innate immune opsonins, such as C-reactive protein, are key players in humoral and cellular immune responses. As the effector mechanism for some therapeutic monoclonal antibodies, and often a contributor to the pathogenesis and progression of autoimmunity, FcRs are promising targets for treating autoimmune diseases. AREAS COVERED: This review discusses the nature of different FcRs and the various mechanisms of their involvement in initiating and modulating immunocyte functions and their biological consequences. It describes a range of current strategies in targeting FcRs and manipulating their interaction with specific ligands, while presenting the pros and cons of these approaches. This review also discusses potential new strategies including regulation of FcR expression and receptor crosstalk. EXPERT OPINION: FcRs are appealing targets in the treatment of inflammatory autoimmune diseases. However, there are still knowledge limitations and technical challenges, the most important being a better understanding of the individual roles of each of the FcRs and enhancement of the specificity in targeting particular cell types and specific FcRs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24521454      PMCID: PMC4019044          DOI: 10.1517/14728222.2014.877891

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  175 in total

1.  Soluble FcgammaRIIIa as a marker for rheumatoid arthritis: the use of genetics in selected populations to study pathogenetic pathways.

Authors:  Tom W J Huizinga; Andreea Ioan-Facsinay
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

2.  Identification of multiple genetic susceptibility loci in Takayasu arteritis.

Authors:  Güher Saruhan-Direskeneli; Travis Hughes; Kenan Aksu; Gokhan Keser; Patrick Coit; Sibel Z Aydin; Fatma Alibaz-Oner; Sevil Kamalı; Murat Inanc; Simon Carette; Gary S Hoffman; Servet Akar; Fatos Onen; Nurullah Akkoc; Nader A Khalidi; Curry Koening; Omer Karadag; Sedat Kiraz; Carol A Langford; Carol A McAlear; Zeynep Ozbalkan; Askin Ates; Yasar Karaaslan; Kathleen Maksimowicz-McKinnon; Paul A Monach; Hüseyin T Ozer; Emire Seyahi; Izzet Fresko; Ayse Cefle; Philip Seo; Kenneth J Warrington; Mehmet A Ozturk; Steven R Ytterberg; Veli Cobankara; A Mesut Onat; Joel M Guthridge; Judith A James; Ercan Tunc; Nurşen Duzgun; Muge Bıcakcıgil; Sibel P Yentür; Peter A Merkel; Haner Direskeneli; Amr H Sawalha
Journal:  Am J Hum Genet       Date:  2013-07-03       Impact factor: 11.025

Review 3.  Rituximab-associated infections.

Authors:  Juan C Gea-Banacloche
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

4.  Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.

Authors:  A Ruyssen-Witrand; S Rouanet; B Combe; M Dougados; X Le Loët; J Sibilia; J Tebib; X Mariette; A Constantin
Journal:  Ann Rheum Dis       Date:  2012-02-25       Impact factor: 19.103

5.  Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide.

Authors:  M Marino; M Ruvo; S De Falco; G Fassina
Journal:  Nat Biotechnol       Date:  2000-07       Impact factor: 54.908

6.  Assessment of autoimmunity in patients with chronic urticaria.

Authors:  L J Tong; G Balakrishnan; J P Kochan; J P Kinét; A P Kaplan
Journal:  J Allergy Clin Immunol       Date:  1997-04       Impact factor: 10.793

7.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

8.  Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases.

Authors:  Naotake Tsuboi; Kenichi Asano; Michael Lauterbach; Tanya N Mayadas
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

9.  Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes.

Authors:  A Jönsen; I Gunnarsson; B Gullstrand; E Svenungsson; A A Bengtsson; O Nived; I E Lundberg; L Truedsson; G Sturfelt
Journal:  Rheumatology (Oxford)       Date:  2007-06-27       Impact factor: 7.580

10.  Identity of the elusive IgM Fc receptor (FcmuR) in humans.

Authors:  Hiromi Kubagawa; Satoshi Oka; Yoshiki Kubagawa; Ikuko Torii; Eiji Takayama; Dong-Won Kang; G Larry Gartland; Luigi F Bertoli; Hiromi Mori; Hiroyuki Takatsu; Toshio Kitamura; Hiroshi Ohno; Ji-Yang Wang
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more
  18 in total

1.  Apoptotic Debris Accumulates on Hematopoietic Cells and Promotes Disease in Murine and Human Systemic Lupus Erythematosus.

Authors:  SunAh Kang; Jennifer L Rogers; Andrew J Monteith; Chuancang Jiang; John Schmitz; Stephen H Clarke; Teresa K Tarrant; Young K Truong; Marilyn Diaz; Yuri Fedoriw; Barbara J Vilen
Journal:  J Immunol       Date:  2016-04-08       Impact factor: 5.422

2.  Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI.

Authors:  Masato Kiyoshi; Jose M M Caaveiro; Takeaki Kawai; Shinya Tashiro; Teruhiko Ide; Yoshiharu Asaoka; Kouta Hatayama; Kouhei Tsumoto
Journal:  Nat Commun       Date:  2015-04-30       Impact factor: 14.919

3.  FcγRIIB mediates antigen-independent inhibition on human B lymphocytes through Btk and p38 MAPK.

Authors:  Shiang-Jong Tzeng; Wan-Yu Li; Hui-Ying Wang
Journal:  J Biomed Sci       Date:  2015-10-16       Impact factor: 8.410

4.  Free and complexed-secretory immunoglobulin A triggers distinct intestinal epithelial cell responses.

Authors:  R Salerno-Goncalves; F Safavie; A Fasano; M B Sztein
Journal:  Clin Exp Immunol       Date:  2016-07-26       Impact factor: 4.330

5.  A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.

Authors:  Gargi Roy; Tom Martin; Arnita Barnes; Jihong Wang; Rod Brian Jimenez; Megan Rice; Lina Li; Hui Feng; Shu Zhang; Raghothama Chaerkady; Herren Wu; Marcello Marelli; Diane Hatton; Jie Zhu; Michael A Bowen
Journal:  MAbs       Date:  2018-02-22       Impact factor: 5.857

Review 6.  Novel Treatments in Myasthenia Gravis.

Authors:  Deepak Menon; Carolina Barnett; Vera Bril
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

Review 7.  Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms.

Authors:  Kashyap R Patel; Jacob T Roberts; Adam W Barb
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

8.  Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions.

Authors:  O S Qureshi; T F Rowley; F Junker; S J Peters; S Crilly; J Compson; A Eddleston; H Björkelund; K Greenslade; M Parkinson; N L Davies; R Griffin; T L Pither; K Cain; L Christodoulou; L Staelens; E Ward; J Tibbitts; A Kiessling; B Smith; F R Brennan; M Malmqvist; F Fallah-Arani; D P Humphreys
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

Review 9.  The physiology of foamy phagocytes in multiple sclerosis.

Authors:  Elien Grajchen; Jerome J A Hendriks; Jeroen F J Bogie
Journal:  Acta Neuropathol Commun       Date:  2018-11-19       Impact factor: 7.801

10.  Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions.

Authors:  Tania F Rowley; Shirley J Peters; Mike Aylott; Robert Griffin; Nicola L Davies; Louise J Healy; Rona M Cutler; Alison Eddleston; Thomas L Pither; Joshua M Sopp; Oliver Zaccheo; Gianluca Fossati; Katharine Cain; Andrew M Ventom; Hanna Hailu; Eleanor J Ward; John Sherington; Frank R Brennan; Farnaz Fallah-Arani; David P Humphreys
Journal:  Commun Biol       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.